Evidence map›Paper›PMID 42292857›Full record

ArticleMedComm2026

Stearoyl-CoA Desaturase-1 Drives Tumor Growth by Interacting With Histone Deacetylase-2 and Deacetylating Nucleophosmin-1.

Coline Wery, Laetitia Montero-Ruiz, Eric Bonneil, Mohammad Farran, Robin Jehay, Quentin Herrara Garfia, Gregory Fettweis, Silvia Blacher, Charles Pottier, Gael Cobraiville and 6 more

Abstract read
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Coline WeryCancer Metabolism and Tumor Microenvironment Lab GIGA-Cancer GIGA Institute University of Liège Liège Belgium.
Laetitia Montero-RuizCancer Metabolism and Tumor Microenvironment Lab GIGA-Cancer GIGA Institute University of Liège Liège Belgium.
Eric BonneilInstitute for Research in Immunology and Cancer (IRIC) University of Montréal Montréal Canada.
Mohammad FarranCancer Metabolism and Tumor Microenvironment Lab GIGA-Cancer GIGA Institute University of Liège Liège Belgium.
Robin JehayCancer Metabolism and Tumor Microenvironment Lab GIGA-Cancer GIGA Institute University of Liège Liège Belgium.
Quentin Herrara GarfiaCancer Metabolism and Tumor Microenvironment Lab GIGA-Cancer GIGA Institute University of Liège Liège Belgium.
Gregory FettweisLaboratory of Gene Expression and Cancer GIGA Institute University of Liège Liège Belgium.
Silvia BlacherLaboratory of Tumor and Development Biology GIGA Institute University of Liège Liège Belgium.
Charles PottierCancer Metabolism and Tumor Microenvironment Lab GIGA-Cancer GIGA Institute University of Liège Liège Belgium.
Gael CobraivilleLaboratory for the Analysis of Medicines CIRM Institute University of Liège Liège Belgium.
Yasmine BoumahdMetastasis Research Laboratory GIGA-Cancer GIGA Institute University of Liège Liège Belgium.
Olivier PeulenMetastasis Research Laboratory GIGA-Cancer GIGA Institute University of Liège Liège Belgium.
Agnès NoëlLaboratory of Tumor and Development Biology GIGA Institute University of Liège Liège Belgium.
Franck DequiedtLaboratory of Gene Expression and Cancer GIGA Institute University of Liège Liège Belgium.
Marianne FilletLaboratory for the Analysis of Medicines CIRM Institute University of Liège Liège Belgium.
Nor Eddine SounniCancer Metabolism and Tumor Microenvironment Lab GIGA-Cancer GIGA Institute University of Liège Liège Belgium.ORCID https://orcid.org/0000-0001-9962-9236

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The adaptation of lipid metabolism in cancer cells, driven by changes in the tumor microenvironment, presents major challenges for cancer therapy. Here, we addressed the problem of altered lipid metabolism and its role in cancer progression and therapeutic resistance. We demonstrate that hypoxia upregulates the key desaturase, stearoyl-CoA desaturase-1 (SCD1), and the lipid droplet (LD) protein PLIN2, thus promoting lipid metabolic adaptation, cell proliferation, migration, and tumor growth. We found that SCD1 and PLIN2 are essential and interdependent for LD formation. PLIN2 supports cell survival under hypoxic and metabolic stress, whereas SCD1 sustains cancer cell proliferation upon reoxygenation. In addition, we found that SCD1 expression in cancer cells affects nonhistone protein deacetylation, whereas PLIN2 expression enhances protein acetylation. Among these proteins, nucleophosmin(NPM1), a tumor suppressor and regulator of p53, was destabilized through SCD1-dependent deacetylation. In addition, SCD1 interacts with NPM1, influences its cellular localization, and recruits histone deacetylase-2 (HDAC2) to the complex. Notably, we observed that knockdown of SCD1 in vitro or its pharmacological inhibition in vivo enhances cancer cell sensitivity to HDAC inhibitors. Our findings underscore the role of SCD1 in reshaping the cellular acetylome and suggest that targeting SCD1 could sensitize cancer cells to HDAC inhibitors, highlighting a promising therapeutic strategy.

Indexed as

cancer drug resistanceHDACslipid dropletsnonhistone protein deacetylationNPM1SCD1

Identifiers

PMID42292857
PMCPMC13260692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.